This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexate or gemcitabine or romidepsin, in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Taking part in a clinical trial may be the best treatment choice for some non-Hodgkin lymphoma (NHL) patients. Clinical trials are under way to develop treatments that increase the remission rate of or cure the disease. Today's standard treatments for cancer are based on earlier clinical trials. The purpose of this study is to determine whether Nivolumab is effective in the treatment of DLBCL in patients that have failed or are ineligible for ASCT. The purpose of this study is to evaluate venetoclax, bendamustine and rituximab as induction therapy in eligible untreated patients. The primary objective of this book is to provide the specialists involved in the clinical management and experimental research in hematological diseases with comprehensive and concise information on some important theoretical and practical ... The video lasts for 2 minutes. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. The purpose of this study is to determine whether a blood test can accurately detect whether if the participant's lymphoma has come back after completion of initial chemotherapy treatment for their aggressive B-cell Non-Hodgkin lymphoma. The purpose of this study is to create a long-term, prospective database of cutaneous lymphoma that will lead to a better understanding of the biological behavior of cutaneous lymphomas as well as the effectiveness of interventions. RTX and BEN are both approved in many countries for the treatment of lymphomas. ATG-101 was designed to activate anti-tumor immune effectors, by simultaneously blocking the binding of PD-L1/PD-1 and inducing 4-1BB stimulation. The purpose of this study is to determine the side effects of treatment with Nivolumab by itself or in combination in patients with relapsed/refractory hematologic malignancies. Diffuse Large B-cell lymphoma (DLBCL) is a fast-growing and aggressive type of lymphoma. Others interfere with the ability of cancer cells to grow and spread. The Phase 1 portion of this study will determine the safety of TAS4464 and the most appropriate dose for patients with Multiple Myeloma or Lymphoma. I’m so very happy and so grateful to get my life back which I took. The purpose of this study is to evaluate the safety, tolerability, drug/body interactions, and treatment effects of a new drug known as BGB-3111 in patients who have B-cell lymphoid malignancies. AXL was identified as a potential therapeutic target in chronic lymphocytic leukemia (CLL). To evaluate the efficacy and safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (placebo-R-CHOP) chemotherapy in patients who have previously untreated ABC type DLBCL. There’s support there just waiting for you to ask. In this volume, we have chosen to discuss several of these steps, which we feel are clearly making a positive impact on the field of lymphomas and which soon should make a major difference in therapeutic results. Patients will be tested to see if there is a difference in side effects between the 2 groups. Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system.NHL is a term that's used for many different types of lymphoma … This is a Phase 1b/2 open-label study to evaluate the safety/efficacy of MEDI-551 + MEDI0680 (AMP-514) in participants with relapsed or refractory aggressive B-cell lymphomas who have failed 1-2 prior lines of therapy. A guide to the diagnosis and treatment of Hodgkin lymphoma in adults. Includes information on support services. Relapsed B-cell non-Hodgkin lymphoma clinical trials are progressing more and more every day. Suitable for patients with classical Hodgkin lymphoma who have not yet received treatment. The Leukemia & Lymphoma Society continues to invest funds in NHL research. Doctor. The purpose of the trial is to determine the maximum tolerated dose and the recommended phase 2 dose as well as to establish the safety profile of GEN3013 (DuoBody®-CD3xCD20) in patients with Relapsed, Progressive or Refractory B-Cell Lymphoma. After the determination of the maximum tolerated dose this dose will be utilized in an expansion cohort or subjects with refractory neuroendocrine tumors (NET) or adrenocortical carcinoma (ACC) tumors. This book examines in detail the current treatment options for first-line, relapsed, and refractory Hodgkin lymphoma and the management appropriate in special clinical circumstances, including in the elderly, pregnant women, and those with ... In order to take part, patients must have disease that has returned after successful treatment (relapsed) or that has never responded to treatment (refractory). Others find cancer cells and help kill them or carry cancer-killing substances to them. Taking part in a clinical trial may be the best therapy for some non-Hodgkin lymphoma (NHL) patients. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Read … Patients with non-ABC subtype (determined by gene expression profiling) will be allocated to Arm A while patients with ABC (activated B-cell type) subtype will be allocated to Arm B. The agency will make its decision on parsaclisib for the treatment of relapsed or refractory follicular lymphoma after two prior systemic therapies by Aug. 30, 2022. The table below shows a list of The Lymphoma Group's current clinical trials open for recruitment for Hodgkin lymphoma patients. Monoclonal antibodies, such as varlilumab and nivolumab, may work by stimulating the immune system to attack cancer tumor cells. A clinical trial to safety and effectiveness of new treatment NP30179 given alone or in combination with Obinituzumab in patients with B-cell non-Hodgkin’s lymphomas. This book is a pocket guide to the practice of PET/CT imaging of Hodgkin’s lymphoma. Both types develop when white blood cells become cancerous and form lumps (swollen lymph glands) in your body. Patients will be randomized to receive either lenalidomide or placebo for twelve 28-day cycles in combination with rituximab. Taking part in a clinical trial may be the best treatment choice for some Hodgkin lymphoma (HL) patients. The Leukemia & Lymphoma Society continues to invest funds in NHL research. The purpose of this study is is to assess the side effects and best dose of akt inhibitor MK2206 when given together with bendamustine hydrochloride and rituximab, and to see how well they work in treating patients with treatment resistant chronic lymphocytic leukemia or small lymphocytic lymphoma. AN OPEN-LABEL, PHASE 2 BASKET STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC ACTIVATING HER MUTATIONS. Found inside – Page 15Clinical Trials M any people with non - Hodgkin's lymphoma take part in clinical trials ( research studies ) . Doctors conduct clinical trials to learn about the effectiveness and side effects of new treatments . … Other trials are looking at new ways of giving standard chemotherapy drugs for different types and stages of lymphoma. Patients must be receiving chemotherapy, including asparaginase, and have a central line (a catheter inserted for administration of medications and blood sampling). A Phase 1 Clinical Trial of Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. It’s a really warm feeling knowing that what you did has helped other people. The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of CFT7455 administered orally in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) administered once a day (QD) as a single agent and in combination with dexamethasone. Trial Search: "non-hodgkin's lymphoma". Email. Our purpose for this study is to help design a therapy plan that can decrease extra radiation exposure to your heart during radiotherapy. This text provides a state-of-the-art overview on Non-Hodgkin's lymphoma (NHL) in children and adolescents. A transplant using donor cells is called an allogenic transplant. To help doctors decide who needs further treatment and who does not, researchers are looking at: Research is looking at new chemotherapy drug combinations for some types of NHL. Non-Hodgkin’s lymphoma (also called NHL) is a cancer that starts in white blood cells called lymphocytes, which are cells of the lymph (or lymphatic) system. ICH GCP. This pilot clinical trial studies how well buparlisib works in treating patients with non-Hodgkin lymphoma that has returned or does not respond to treatment. Note: romidepsin will not be used as a single-agent comparator in countries that do not permit its use at this time. Their website has a section called trialslink where you can see information about lymphoma clinical trials. A guide to our current trials open for recruitment. Exploring Mechanisms of Action and Resistance of Therapeutic Agents in Patients with B-cell Malignancies, Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides, A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma, A Study of Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma, Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL), A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM), A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies, LS1681: A Study of AR160 in Treating Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma, Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma, A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Hematologic Malignancies, A Study to Evaluate the Effectiveness and Safety of P276-00 for Mantle Cell Lymphoma that has Returned and/or is Resistant to Treatment, A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL), A Study of TAK-981 in Combination with Rituximab in Participants with Relapsed/Refractory (r/r) CD20-positive (CD20+) Non-Hodgkin Lymphoma (NHL), Household Controls for Clinical and Epidemiological Studies in Lymphoma and Chronic Lymphocytic Leukemia, Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma, Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma, Study to Evaluate the Safety and Effectiveness of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Relapsed/Refractory Large B-cell Lymphoma, Building a Healthy Body after Cancer: Challenges and Opportunities in Healthy Exercise after Treatment for Young Adult Lymphoma Survivors, Bortezomib, Rituximab, and Dexamethasone with or without Temsirolimus in Treating Patients with Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma, Axicabtagene Ciloleucel Expanded Access Study, A Safety Study of SEA-TGT in Patients With Advanced Cancer, A Clinical Study Using MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies, Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma, A Study Evaluating the Effectiveness and Safety of Axicabtagene Ciloleucel in Subjects with High-Risk Large B-Cell Lymphoma, Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma, Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides, A Study to Compare Three Chemotherapy Regimens for the Treatment of Patients with Newly- diagnosed Mantle Cell Lymphoma, An Effectiveness and Safety Study of Daratumumab in Relapsed/Resistant Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma, Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma, A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies, A Study to Evaluate Feasibility of In Vivo Sensitivity Screen Using Direct Tumor Microinjection and FDG-PET in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer, Safety Study of SEA-CD40 in Cancer Patients, A Study Evaluating the Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma, A Study to Evaluate LOXO-305 Vs. Approved BTK Inhibitor Approved Drugs to Treat Patients with Mantle Cell Lymphoma, Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas, Panobinostat and Everolimus in Treating Patients with Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma, A Study of Investigational Immunotherapy to Determine the Safety and Effectiveness of Nivolumab and Daratumumab, with or without Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Hematologic Malignancies, Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL), A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients, A Study to Provide Access to CTL019 Out of Specification Managed Access Program (MAP) for ALL or DLBCL Patients, A Study to Evaluate the Use of Nivolumab and Pomalidomide Combination for Relapsed/Refractory Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma, Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency, A Study Evaluating the Safety and Effectiveness of JCAR017 to Treat Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), A Study of Using Bortezomib and Combination Chemotherapy in Treating Children with Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL, A Study to Assess CART19 for B Cell Malignancies, Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas, Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors, FT516 in Subjects With Advanced Hematologic Malignancies, A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies, A Study to Evaluate the Safety and Effectiveness of JBH492 in Patients with Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma, Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma, A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy, Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies, A Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies, A Study of Chemotherapy-induced Peripheral Neuropathy, FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides), Study Treating Patients with Relapsed or Refractory Aggressive B-cell Lymphomas Using Nivolumab with or without Varlilumab, A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas, A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL), A Study to Evaluate Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation, Immunogenicity and Safety of Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients with Hematologic Malignancies and Associated Precursors, A Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma, Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155), Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL), A Study to Evaluate the Effectiveness and Safety of Cobomarsen (MRG-106) vs. The primary purpose of this study is to evaluate the effectiveness and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype. Welcome to Lymphoma TrialsLink. One type of immunotherapy is CAR T-cell therapy. For non-Hodgkin lymphoma, researchers are looking at: BI 1206; GSK2857916; ofatumumab; mogamulizumab; glofitamab; copanlisib; ibrutinib; bortezomib; fostamatinib. Asher, Arash. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Treatment trials which apply specifically to your search: 0C-14-2. This trial will look at a drug called SGN-TGT to find out whether it is safe for patients with solid tumors and lymphomas. Moffitt Cancer Center’s clinical trial program is one of the most robust in the region, conducting numerous studies that focus on both Hodgkin and non-Hodgkin lymphoma. Bortezomib may also stop the growth of cancer cells by blocking blood flow to the tumor. Research is looking at using stem cells collected from the umbilical cords of newborn babies. Dan Symes, Andrew Schorr. Search for closest city to find more detailed information on a research study in your area. Expansion to occur at maximum tolerated dose (MTD), or if not reached, at optimal biologic dose (OBD). All ages Under 18 Over 18. Experimental design: Forty-two previously treated patients (32 patients with NHL and 10 patients with HD) were enrolled on the study. Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma. This randomized phase II trial studies how well rituximab and combination chemotherapy with or without lenalidomide work in treating patients with newly diagnosed stage II-IV diffuse large B cell lymphoma. IMO-8400 is an oligonucleotide specifically designed to inhibit ligand activation of TLRs 7,8, and 9. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. NCT03888105: A phase 2, non-randomized clinical trial for treatment with an Anti-CD20 and Anti-CD3 Bispecific Antibody of patients with B-Cell Non-Hodgkin Lymphoma, grades to 3b who have received at least 2 lines of prior systemic therapy. This is an opportune time to consider a Research Topic considering when what we have learned about the PI3K signalling module in lymphocyte biology and how this is making an impact on clinical immunology and haematology. T cells fight infections and, in some cases, can also kill cancer cells. The purpose of this study is to determine the efficacy and safety of CTL019 in adult patients with relapsed or resistant diffuse large B-cell lymphoma. In: J Clin Oncol 36, 2018; Abstract 7547. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-sepcific cohorts. Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. In a mini transplant you have a lower dose of chemotherapy, also called low intensity treatment. Therapeutic Advances in Hematology. This phase II trial is studying how well panobinostat works in treating patients with relapsed or refractory non-Hodgkin lymphoma. ATG-101 was designed to activate anti-tumor immune effectors, by simultaneously blocking the binding of PD-L1/PD-1 and inducing 4-1BB stimulation. Giving bortezomib together with combination chemotherapy may kill more cancer cells. In: J Clin Oncol 36, 2018; Abstract 7520. In addition, we will look to survivors to guide us on the particular ways in which a health care institution might support them in physical activity. PURPOSE: This phase I/II trial is studying the side effects and best dose of giving everolimus and lenalidomide together and to see how well they work in treating patients with relapsed or refractory non-Hodgkin or Hodgkin lymphoma. Treatment: Clinical trial of ibrutinib + rituximab, consolidated chemo of 4 cycles of Hyper-CVAD. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving everolimus together with lenalidomide may be an effective treatment for lymphoma. For example, they can block signals that tell cells to grow. This is especially true for those who went on to have a stem cell transplant. They hope to learn more about the causes and possible treatments. Clinical Trials and Observations Borrelia infection and risk of non-Hodgkin lymphoma. This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency.
clinical trial for non hodgkin's lymphoma 2021